Back to top
more

Calyxt, Inc. (CLXT)

(Delayed Data from NSDQ)

$15.70 USD

15.70
112,120

+0.19 (1.23%)

Updated May 3, 2019 04:00 PM ET

After-Market: $15.67 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Calyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Bears are Losing Control Over Calyxt (CLXT), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Calyxt (CLXT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of 22.22% and 96.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Inovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Global Blood (GBT) delivered earnings and revenue surprises of -19.30% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of -26.32% and 69.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Calyxt (CLXT) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Calyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of -10.53% and 50.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Calyxt (CLXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clorox (CLX) Queues Up For Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Clorox (CLX) witnesses manufacturing and logistics costs. These along with higher selling and administrative costs might have hurt the bottom line in third-quarter fiscal 2021.

Calyxt (CLXT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Calyxt (CLXT) delivered earnings and revenue surprises of -32.00% and 77.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Calyxt (CLXT) Ahead of Earnings?

by Zacks Equity Research

Calyxt (CLXT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Are You Looking for a Top Momentum Pick? Why Calyxt (CLXT) is a Great Choice

by Zacks Equity Research

Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Hain Celestial's (HAIN) Q2 Earnings Beat on Higher Margins

by Zacks Equity Research

Smooth execution of transformation plan aided Hain Celestial's (HAIN) second-quarter fiscal 2021 performance. It expects sustained margin growth for fiscal 2021.

Moving Average Crossover Alert: Calyxt (CLXT)

by Zacks Equity Research

Calyxt (CLXT) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

The Zacks Analyst Blog Highlights: BlackBerry, Calyxt, DAQO New Energy, Avis Budget Group and 3D Systems

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BlackBerry, Calyxt, DAQO New Energy, Avis Budget Group and 3D Systems

Sejuti Banerjea headshot

5 High-Flying Stocks Set to Move Higher

by Sejuti Banerjea

These 5 stocks have good reason for further upside.

Here's Why Calyxt (CLXT) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Calyxt (CLXT) a New Strong Buy Stock

by Zacks Equity Research

Calyxt (CLXT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

Here's How Americans Are Regaining Confidence: 5 Picks

by Sanghamitra Saha

U.S. consumer confidence gained in May and beat the expectations of economists polled by Dow Jones.

    Calyxt (CLXT) Moves to Strong Buy: Rationale Behind the Upgrade

    by Zacks Equity Research

    Calyxt (CLXT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

    Rajani Lohia headshot

    Agriculture Operations Outlook: Tariffs to Mar Organic Gains

    by Rajani Lohia

    The Zacks Agriculture - Operations industry should witness gains from wooing customers with organic solutions for crop production. Yet, tariff-related headwinds remain threats to top line.